Clinical Report: The Role of IL-37 and IL-38 in Modulating CRS in CAR-T Therapy

Overview

This mini-review discusses the roles of IL-37 and IL-38 in regulating cytokine release syndrome (CRS) associated with CAR-T therapy in multiple myeloma.

Background

Multiple myeloma is a challenging hematological malignancy characterized by the proliferation of malignant plasma cells and a highly immunosuppressive microenvironment. Despite advancements in treatment, including CAR-T therapy, the management of CRS remains a significant clinical hurdle. Understanding the mechanisms of cytokine regulation is crucial.

Data Highlights

No numerical data or trial data provided in the article.

Key Findings

• IL-37 suppresses NF-B/MAPK signaling and inflammasome activity, mitigating endothelial injury.
• IL-38 acts as a tissue-resident regulator, modulating macrophage-dendritic cell interactions in the bone marrow.
• Both IL-37 and IL-38 are proposed to function in a phase-dependent regulatory axis during CRS.
• Current standard care for CRS involves IL-6 blockade, but severe cases may persist due to redundant inflammatory signaling.

Clinical Implications

Further research is needed to explore the roles of IL-37 and IL-38 in CRS management.

Conclusion

The roles of IL-37 and IL-38 in modulating CRS warrant further investigation.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. The ASCO Post — Blood Test Can Predict High-Risk Cancers in Patients Treated With CAR-T Related Articles
3. The ASCO Post — Study Examines a Potential Approach to Mitigate CAR T-Cell Therapy Toxicity
4. Frontiers in Oncology — Efficacy and safety of CD38-directed CAR-T cell therapy for multiple myeloma: a systematic review and meta-analysis
5. Blood Cancer Journal — Enhancing CAR T-cell Therapy for Multiple Myeloma: Opportunities for Advancement
6. Blood Test Can Predict High-Risk Cancers in Patients Treated With CAR-T Related Articles
7. Study Examines a Potential Approach to Mitigate CAR T-Cell Therapy Toxicity
8. Efficacy and safety of CD38-directed CAR-T cell therapy for multiple myeloma: a systematic review and meta-analysis
9. Enhancing CAR T-cell Therapy for Multiple Myeloma: Opportunities for Advancement
10. ASTCT CRS Consensus Grading - PDQ Cancer Information Summaries
11. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis
12. Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome related to CAR-T cell therapies